Xylem weakness creates buying opportunity, says Oppenheimer Oppenheimer believes that the recent weakness in Xylem was caused by the company's statement in the middle of Q2 that sales were tracking at the low end of a 1%-3% increase. However, the firm predicts that the company's Q2 results will be boosted by efficiency gains, and it thinks that the results will be in-line and solid. The firm keeps an Outperform rating on the shares.
News For XYL From The Last 14 Days
Check below for free stories on XYL the last two weeks.